Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of aspergillosis
3.2.1.2 Growing awareness of fungal infections
3.2.1.3 Development of new antifungal agents
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited treatment options
3.2.2.2 High treatment costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Acute aspergillosis
5.3 Chronic aspergillosis
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Antifungal drugs
6.2.1 Azoles
6.2.2 Echinocandins
6.2.3 Polyenes
6.2.4 Allylamines
6.2.5 Other antifungal drugs
6.3 Corticosteroids
6.3.1 Prednisolone
6.3.2 Prednisone
6.3.3 Methylprednisolone
6.3.4 Other corticosteroids
6.4 Other drug class
Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.2.1 Tablets
7.2.2 Capsules
7.3 Injections
7.4 Ointments
7.5 Powders
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Astellas Pharma Inc.
10.3 Astra Zeneca PLC
10.4 Basilea Pharmaceutica Ltd.
10.5 Bayer AG
10.6 Endo International plc
10.7 F2G
10.8 GSK plc
10.9 Johnson & Johnson
10.10 Merck & Co., Inc.
10.11 Mayne Pharma Group Limited
10.12 Novartis AG
10.13 PULMATRiX, Inc.
10.14 Takeda Pharmaceutical Company Ltd.
10.15 Viatris Inc.
